Quality of life instruments for liver transplant recipients: Too many choices?
W. Ray Kim – 30 December 2003
Experience with the use of sirolimus in liver transplantation—use in patients for whom calcineurin inhibitors are contraindicated
George J. Chang, Harish D. Mahanty, David Quan, Chris E. Freise, Nancy L. Ascher, John P. Roberts, Peter G. Stock, Ryutaro Hirose – 30 December 2003 – Sirolimus (SRL) provides effective immunosuppression for kidney transplantation and may be useful in patients with delayed allograft function after kidney transplantation. We review our experience with SRL in liver transplant recipients for whom calcineurin inhibitors are undesirable. Fourteen patients with renal insufficiency or acute mental status impairment were administered SRL after liver transplantation (5‐ to 10‐mg load, 1 to 4 mg/d).
Posttransplantation prevention and treatment of recurrent hepatitis C
Andrew K. Burroughs – 30 December 2003 – Key Points
Nonsurgical treatment of hepatocellular carcinoma
Josep M. Llovet, Margarita Sala, Jordi Bruix – 30 December 2003 – Key Points
Pretransplantation tumor necrosis factor‐α production predicts acute rejection after liver transplantation
Andrew J. Bathgate, Patricia Lee, Peter C. Hayes, Kenneth J. Simpson – 30 December 2003 – Immunosuppressive therapy has many adverse effects in both the short and longer term. Tailoring immunosuppression might be possible if pretransplantation parameters predicted rejection. We investigated production of the proinflammatory cytokine, tumor necrosis factor‐α (TNF‐α), and the anti‐inflammatory cytokine, interleukin‐10 (IL‐10), pretransplantation to determine whether there is a relation with acute rejection.
Transplant livers in wilson's disease for hepatic, not neurologic, indications
George J. Brewer, Frederick Askari – 30 December 2003
Adenovirus‐mediated expression of Cu/Zn‐ or Mn‐superoxide dismutase protects against CYP2E1‐dependent toxicity
María José Pérez, Arthur I. Cederbaum – 30 December 2003 – CYP2E1 induction by ethanol is one mechanism by which ethanol creates oxidative stress in the liver. The superoxide dismutases (SODs) are an important antioxidant enzyme defense system against reactive oxygen species (ROS). To investigate the protective role of SOD against CYP2E1‐dependent toxicity, a transfected HepG2 cell line overexpressing CYP2E1 (E47 cells) was infected with adenoviral vectors containing Cu/Zn‐SOD complementary DNA (cDNA) (Ad.SOD1) and Mn‐SOD cDNA (Ad.SOD2).
CC531S‐induced damage of the rat liver sinusoidal endothelial lining is mediated by the Fas/FasL pathway
Katrien Vekemans, Filip Braet, Eddie Wisse – 30 December 2003
Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization
Nicholas A. Shackel, Peter H. McGuinness, Catherine A. Abbott, Mark D. Gorrell, Geoffrey W. McCaughan – 30 December 2003 – Pathogenic molecular pathways in cirrhotic liver diseases such as hepatitis C virus (HCV), autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) are poorly characterized. Differentially expressed genes are often important in disease pathogenesis. Suppression subtractive hybridization (SSH) is a genome‐wide approach that enriches for differentially expressed mRNA transcripts.
Epidemiology of primary hepatic malignancies in U.S. children
Anil Darbari, Keith M. Sabin, Craig N. Shapiro, Kathleen B. Schwarz – 30 December 2003 – The epidemiology of primary hepatic malignancies in U.S. children is poorly characterized. We analyzed the incidence, mortality, and characteristics of primary hepatic malignancies in U.S. residents less than 20 years of age. Fatal primary hepatic malignancies in persons less than 20 years of age, between 1979 and 1996, were identified using the multiple‐cause‐of‐death database (National Center for Health Statistics).